Kombi-Kalz (Colecalciferol, Calcium Carbonate)

Colecalciferol (vitamin D3) is converted in the liver and kidneys to the active hormone calcitriol. Calcitriol binds to vitamin D receptors in the intestinal lining, increasing the expression of calcium‑transport proteins, which enhances dietary calcium absorption and promotes bone mineralisation.

The appropriate dose of Kombi‑Kalz is determined by the prescribing healthcare professional based on the patient’s serum calcium and vitamin D levels, age, renal function and overall clinical condition. Patients should follow the prescriber’s instructions and not self‑adjust the dose.

Safety data for Kombi‑Kalz in pregnancy and lactation are limited. Healthcare providers usually assess the risk‑benefit ratio before prescribing. If supplementation is required, the prescriber will select a dose that meets the nutritional needs while minimising any potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kombi‑Kalz combines calcium carbonate with colecalciferol in a single oral formulation, offering both mineral and vitamin D3 in one product. Compared with separate calcium and vitamin D supplements, it simplifies dosing and may improve adherence, while providing comparable bioavailability when taken with food.

Kombi‑Kalz should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture, heat and direct sunlight to maintain product stability throughout its shelf life.

Kombi‑Kalz is taken orally, usually with a meal to enhance calcium absorption. The tablet or capsule should be swallowed whole with water unless the prescriber advises an alternative method such as splitting or crushing for patients with swallowing difficulties.

The most serious risks include significant hypercalcaemia, which can cause cardiac arrhythmias, kidney stones, and neurological symptoms, as well as rare allergic reactions. Patients should report any signs of persistent nausea, vomiting, excessive thirst, frequent urination or swelling to a healthcare professional promptly.

Kombi‑Kalz is contraindicated in individuals with known hypersensitivity to colecalciferol, calcium carbonate or any excipients, as well as patients with hypercalcaemia, severe renal impairment, or active hyperparathyroidism unless specifically directed by a physician.